Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the pneumonia therapeutics market size evolved in recent years?

The market size for pneumonia therapeutics has seen a swift expansion in the past few years. The market was projected to escalate from $10.35 billion in 2024 and rise to $11.49 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 11.0%. The surge during the historical period was mainly due to an upswing in the occurrence of drug-resistant strains, enhanced awareness about pneumonia prevention, growth in the elderly and those with weakened immune systems, expansion of vaccination programs, and the betterment of healthcare infrastructure.

What are the predictions for the pneumonia therapeutics market size in the coming years?

The market for pneumonia therapeutics is predicted to experience substantial expansion in the upcoming years, escalating to a value of $17.26 billion by 2029 with a compound annual growth rate (CAGR) of 10.7%. Factors leading to this expected growth comprise the rising incidence of antibiotic-resistant strains and the high prevalence of pneumonia particularly in the elderly. Further influencing factors include the widespread adoption of telemedicine enabling early diagnosis, increased health expenditure in developing markets, enhanced funds devoted to infectious disease research and comprehensive awareness campaigns. Key trends for this period include the development of monoclonal antibodies, increasing use of inhalable antibiotics, mRNA-based vaccine innovation, AI-assisted diagnostic tools, the adoption of host-directed therapies, new immunomodulators, and improvements in swift point-of-care diagnostic platforms.

Get your pneumonia therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/pneumonia-therapeutics-global-market-report

What key factors are fueling the growth of the pneumonia therapeutics market?

The proliferation of pneumonia cases is anticipated to propel the growth of the pneumonia therapeutics market. Pneumonia is a lung condition that results in inflammation of the air sacs, often leading to symptoms including cough, fever, and difficulty in breathing. The surge in pneumonia cases could be linked to factors like growing older populations, air contamination, smoking, compromised immune systems, antimicrobial resistance, and the emergence of respiratory diseases, such as COVID-19 or influenza. Therapies for pneumonia aim to tackle the source of the infection, whether bacterial, viral, or fungal, by implementing specific medications while facilitating recovery via oxygen treatment, anti-inflammatory drugs, and managing symptoms. For example, the National Center for Biotechnology Information, a government agency in the United States, indicated in January 2023 that pneumonia impacts around 120 million individuals worldwide every year, leading to about 1.3 million fatalities. Nearly 80% of pneumonia-associated deaths in children occur in those under two years of age in developing nations. Hence, the escalating incidence of pneumonia is prompting the expansion of the pneumonia therapeutics market.

How is the global pneumonia therapeutics market divided into key segments?

The pneumonia therapeutics market covered in this report is segmented –

1) By Product: Drugs, Vaccine, Oxygen Therapy

2) By Infection: Hospital-Acquired Pneumonia (HAP), Community-Acquired Pneumonia (CAP), Ventilator-Associated Pneumonia (VAP)

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By End Use: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Drugs: Antibiotics, Antiviral Drugs, Antifungal Drugs, Corticosteroids, Other Drugs

2) By Vaccine: Pneumococcal Vaccines, Haemophilus Influenzae Type B (Hib) Vaccines, Influenza Vaccines, Other Vaccines

3) By Oxygen Therapy: High-Flow Nasal Cannula (HFNC), Non-Invasive Ventilation (NIV), Mechanical Ventilation, Other Oxygen Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21258&type=smp

Who are the key firms paving the way for growth in the pneumonia therapeutics market?

Major companies operating in the pneumonia therapeutics market are Pfizer Inc., Roche AG, Merck & Co. Inc., AbbVie Inc, Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Shionogi & Co. Ltd, Lupin Limited, Swedish Orphan Biovitrum AB, Nabriva Therapeutics plc, TaiGen Biotechnology Co. Ltd, Aridis Pharmaceuticals Inc., Tergene Biotech Limited.

What are the key trends shaping the future of the pneumonia therapeutics market?

Prominent enterprises in the pneumonia therapeutics market are centered on the creation of novel drug compounds and therapeutic procedures including antibiotic medications, with the intention of combating antibiotic resistance and enhancing patient results. Antibiotic drugs are specific forms of medicines developed to combat bacterial infections. For example, in June 2024, Orchid Pharma Limited, a pharmaceutical firm from India, allied with Cipla Limited, another Indian pharmaceutical entity, to launch cefepime-enmetazobactam. This combination of antibiotics is employed to handle complicated infections such as UTIs and pneumonia, especially those that are resistant to other drugs. This combination aids in the battle against bacterial resistance, which ensures effective treatment while reducing the requirement for stronger antibiotics.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21258

What regions are contributing significantly to the growth of the pneumonia therapeutics market?

North America was the largest region in the pneumonia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumonia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Diphtheria Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diphtheria-global-market-report

Tetanus Toxoid Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tetanus-toxoid-vaccine-global-market-report

Retinal Disorder Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: